NCT Number: NCT05752812
The goal of this observational study is to validate a pretreatment prognostic score (Heidelberg Prognostic Pancreatic Cancer Score - HELPP) in patients with pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* Is the HELPP score able to predict median overall survival in a prospective multi-institutional cohort of patients with pretherapeutic localized non-metastatic pancreatic cancer? * Is the HELPP score able to predict median recurrence-free survival and patterns of recurrence after resection of pancreatic cancer?
Interested in participating?
Request Info18 year–99 year
All sexes
Observational
Vienna, 1090, Austria
Location status: Recruiting
Carl Leonhardt
CONTACT
+43140400 ext. 56470
Carl Leonhardt, MD, MBA
SUB_INVESTIGATOR
Oliver Strobel, MD, MBA
PRINCIPAL_INVESTIGATOR
Accurate pretreatment staging and subsequent prediction of prognosis in pancreatic ductal adenocarcinoma (PDAC) is challenging due to subclinical micrometastasis as well as variations in tumor biology. Moreover, patients with non-metastasized localized PDAC are increasingly treated with neoadjuvant chemotherapy prior to resection.
The investigators recently developed a preoperative prognostic score to predict postoperative outcomes based on routine laboratory biomarkers and the American Society of Anesthesiologists (ASA) score, the HELPP score (Heidelberg Prognostic Pancreatic Cancer Score). Based on a large retrospective analysis of 1197 patients and an external validation cohort the HELPP score was able stratify patients based on expected survival only utilizing routinely available preoperative data. However, prospective validation is currently lacking.
This multi-site prospective observational study aims to prospectively validate the HELPP score in the clinical scenarios described above. Additionally, it aims to investigate its utility regarding median recurrence-free survival and patterns of recurrence. The study includes all consecutive patients with PDAC undergoing exploration (without or without neoadjuvant treatment) with the aim of resection within a timeframe of 12 months (all-comers concept, snapshot study).
The parameters on which the score is based on are routinely available to hospitals worldwide. Simplicity of the grading system facilitates implementation in daily clinical practice. This score could potentially help tailor treatments, aid in patient stratification in clinical trials, and provide new insights into tumor biology.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Date of diagnosis to date of death; assessed up to 60 months
Median overall survival from the time of diagnosis with pancreatic ductal adenocarcinoma to time of death due to any cause.
Time frame: Date of surgery to date of the first evidence of recurrent disease; assessed up to 60 months
Median recurrence-free survival from the date of potentially curative pancreatic surgery for pancreatic ductal adenocarcinoma until detection of the first evidence of recurrent disease either based on cross-sectional imaging or cytology/histology.
Time frame: Date of surgery to date of the first evidence of recurrent disease; assessed up to 60 months
Patterns of recurrence either based on cross-sectional imaging or cytology/histology after potentially curative pancreatic surgery of pancreatic ductal adenocarcinoma. The location of recurrence will be defined based on the first site of recurrence. Only the first site of recurrence will be considered.
Contact information is provided by the study sponsor or research team.
Medical University of Vienna
Other
The HELPP Score: A Pretreatment Prognostic Score to Predict Survival and Patterns of Recurrence in Localized Non-Metastatic Pancreatic Cancer - a Multicenter Prospective Validation Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04400357
Adenocarcinoma, Ampullary Adenocarcinoma
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07562152
Digestive System Diseases, Digestive System Neoplasms
Phoenix, Arizona, United States
View Trial DetailsNCT07090499
Adenocarcinoma, Adenocarcinoma Of Esophagus
Duarte, California, United States
View Trial DetailsNCT05208762
Adenocarcinoma, Breast Diseases
Birmingham, Alabama, United States
View Trial Details